Skip to main content
. 2023 Mar 15;24(6):5623. doi: 10.3390/ijms24065623

Figure 4.

Figure 4

CD44 is a downstream target of NF-kB signaling in MyD88L265P-expressing lymphoma cells. (A) Schematic representation of the signaling pathway triggered by the autodimerization of MyD88L265P and the role of TAK1 inhibitor 5Z-7-oxozeaenol (5Z7O) in the pathway. (B) Validation of the TAK1 inhibitor 5Z-7-oxozeaenol (5Z7O) in THP1 Dual cell lines. Cells were treated with 1 µM 5Z7O and 250 ng/mL DOX as indicated. After 24 h, MyD88- and MyD88L265P-induced NF-kB activation was measured with the QUANTI-Blue method. (C) qPCR analysis of MyD88 expression levels in U2932 cell lines after 24 h DOX and subsequent 24 h 5Z7O (1 µM) treatments. (D) qPCR analysis of expression levels of BATF, LGALS3, NFKBIZ, and CD44 in U2932 cell lines after 24 h DOX (250 ng/mL) and subsequent 24 h 5Z7O (1 µM) treatments. (ns, not significant for p > 0.05, * for p ≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001, **** for p ≤ 0.0001).